The saphenous vein graft (SVG) remains the most commonly used conduit in coronary artery bypass grafting (CABG), yet its limited long-term patency adversely affects patient outcomes. SVG failure is a multistage pathological process, characterized by early thrombosis, intermediate intimal hyperplasia, and late atherosclerotic degeneration. These changes are driven by endothelial dysfunction induced by ischemia-reperfusion and mechanical injury, smooth muscle cell phenotypic modulation, inflammatory activation, and conventional cardiovascular risk factors. Preventive strategies for SVG failure have increasingly focused on both surgical and pharmacological optimization. Surgical approaches include appropriate target vessel and anastomotic site selection, refinement of SVG harvesting techniques (notably the no-touch technique and endoscopic vein harvesting), optimization of graft configurations, and routine intraoperative graft flow assessment. Postoperative secondary prevention is essential, as antithrombotic and lipid-lowering therapies have been shown to reduce SVG occlusion. In addition, emerging therapies, including gene-based interventions, antiproliferative agents, novel graft preservation solutions, and external vein graft supports, show promise in improving SVG durability. Integrated multimodal strategies may further reduce SVG failure and improve long-term outcomes after CABG. This article provides a review of researches related to SVG failure, including the mechanisms of failure, intraoperative preventive measures, pharmacological prevention, and recent advances in treatment, aiming to offer insights for clinical diagnosis, treatment and future studies.
Citation：
HE Liaoming, XIERAILI Tiemuerniyazi, SONG Yangwu, FENG Wei. Research progress on the mechanisms and prevention of saphenous vein graft failure after coronary artery bypass grafting. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2026, 33(3): 475-483. doi: 10.7507/1007-4848.202401046
Copy
Copyright ? the editorial department of Chinese Journal of Clinical Thoracic and Cardiovascular Surgery of West China Medical Publisher. All rights reserved
| 1. |
|
| 2. |
|
| 3. |
|
| 4. |
|
| 5. |
|
| 6. |
|
| 7. |
|
| 8. |
|
| 9. |
|
| 10. |
|
| 11. |
|
| 12. |
|
| 13. |
|
| 14. |
|
| 15. |
|
| 16. |
|
| 17. |
|
| 18. |
|
| 19. |
|
| 20. |
|
| 21. |
|
| 22. |
|
| 23. |
|
| 24. |
|
| 25. |
|
| 26. |
|
| 27. |
|
| 28. |
|
| 29. |
|
| 30. |
|
| 31. |
|
| 32. |
Jiao H, Li J, Bai Y, et al. Patency and adverse outcomes of sequential vs. individual saphenous vein grafts in coronary artery bypass: a meta-analysis. Front Cardiovasc Med, 2022, 9: 944717.
|
| 33. |
|
| 34. |
Tseng YH, Kao CC, Lin CC, et al. Do the paths of sequential vein grafts influence the outcomes of coronary artery bypass surgeries? Heart Surg Forum, 2020, 23(1): E001-E006.
|
| 35. |
|
| 36. |
|
| 37. |
|
| 38. |
|
| 39. |
|
| 40. |
|
| 41. |
|
| 42. |
|
| 43. |
|
| 44. |
|
| 45. |
|
| 46. |
|
| 47. |
|
| 48. |
|
| 49. |
Park SJ, Jo AJ, Kim HJ, et al. Real-world outcomes of on- vs. off-pump coronary bypass surgery: result from korean nationwide cohort. Ann Thorac Surg, 2022, 113(6): 1989-1998.
|
| 50. |
|
| 51. |
|
| 52. |
|
| 53. |
|
| 54. |
|
| 55. |
|
| 56. |
|
| 57. |
|
| 58. |
|
| 59. |
|
| 60. |
|
| 61. |
|
| 62. |
|
| 63. |
|
| 64. |
|
| 65. |
|
| 66. |
|
| 67. |
|
| 68. |
|
| 69. |
|
| 70. |
|
| 71. |
|
| 72. |
|
| 73. |
|
| 74. |
|
| 75. |
Fan Y, Ge J. Pentoxifylline prevents restenosis by inhibiting cell proliferation via p38MAPK pathway in rat vein graft model. Cell Transplant, 2022, 31: 9636897221122999.
|
| 76. |
|
| 77. |
|
| 78. |
Gao M, Ding X, Lian X, et al. Administration of a new nano delivery system coated with Tirofiban to prevent early thrombosis of vein graft. Perfusion, 2024, 39(6):1080-1087.
|
| 79. |
|
| 80. |
|
| 81. |
|
| 82. |
|
| 83. |
|
| 84. |
|
| 85. |
|
| 86. |
|
| 87. |
|
| 88. |
|
| 89. |
|
| 90. |
|
| 91. |
|
| 92. |
|
| 93. |
|
| 94. |
|
| 95. |
|
| 96. |
|
| 97. |
|
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.
- 10.
- 11.
- 12.
- 13.
- 14.
- 15.
- 16.
- 17.
- 18.
- 19.
- 20.
- 21.
- 22.
- 23.
- 24.
- 25.
- 26.
- 27.
- 28.
- 29.
- 30.
- 31.
- 32. Jiao H, Li J, Bai Y, et al. Patency and adverse outcomes of sequential vs. individual saphenous vein grafts in coronary artery bypass: a meta-analysis. Front Cardiovasc Med, 2022, 9: 944717.
- 33.
- 34. Tseng YH, Kao CC, Lin CC, et al. Do the paths of sequential vein grafts influence the outcomes of coronary artery bypass surgeries? Heart Surg Forum, 2020, 23(1): E001-E006.
- 35.
- 36.
- 37.
- 38.
- 39.
- 40.
- 41.
- 42.
- 43.
- 44.
- 45.
- 46.
- 47.
- 48.
- 49. Park SJ, Jo AJ, Kim HJ, et al. Real-world outcomes of on- vs. off-pump coronary bypass surgery: result from korean nationwide cohort. Ann Thorac Surg, 2022, 113(6): 1989-1998.
- 50.
- 51.
- 52.
- 53.
- 54.
- 55.
- 56.
- 57.
- 58.
- 59.
- 60.
- 61.
- 62.
- 63.
- 64.
- 65.
- 66.
- 67.
- 68.
- 69.
- 70.
- 71.
- 72.
- 73.
- 74.
- 75. Fan Y, Ge J. Pentoxifylline prevents restenosis by inhibiting cell proliferation via p38MAPK pathway in rat vein graft model. Cell Transplant, 2022, 31: 9636897221122999.
- 76.
- 77.
- 78. Gao M, Ding X, Lian X, et al. Administration of a new nano delivery system coated with Tirofiban to prevent early thrombosis of vein graft. Perfusion, 2024, 39(6):1080-1087.
- 79.
- 80.
- 81.
- 82.
- 83.
- 84.
- 85.
- 86.
- 87.
- 88.
- 89.
- 90.
- 91.
- 92.
- 93.
- 94.
- 95.
- 96.
- 97.
